B Acute Lymphoblastic Leukemia

@drclaireroddie discusses obecabtagene autoleucel in patients w/ R/R B-cell acute lymphoblastic leukemia, details the key topline findings from the FELIX trial, and provides insights on unmet needs that remain for this patient population. #leusm https://t.co/Bpr4ChREua (@OncLive)

Join Drs @AmeliaLangston and Bijal Shah as they discuss CAR T-cell therapy for B-cell acute lymphoblastic leukemia, including clinical trials and real-world experience from their centers. https://t.co/bch33fwIsc (@Medscape)

WATCH: @RoloffGreg, of @UChicagoMed, discusses real-world outcomes from treatment with brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. https://t.co/TdZaSk61zY (@OncLive)

Join Drs @AmeliaLangston and Bijal Shah as they discuss CAR T-cell therapy for B-cell acute lymphoblastic leukemia, including clinical trials and real-world experience from their centers. #OncTwitter https://t.co/N5F5CB2KvY (@MedscapeOnc)

According to data presented at #ASCO2023 by @drclaireroddie, 76% of adults with relapsed or refractory B-cell acute lymphoblastic leukemia achieved complete response to treatment with obecabtagene autoleucel. https://t.co/N8K8LneHjT (@HemOncToday)

Brexu-cel elicited high rates of complete remission s/ MRD negativity in real-world patients w/ R/R B-cell acute lymphoblastic leukemia who received the CAR T-cell product as post-approval, standard-of-care treatment. @RoloffGreg @UChicagoMed #ASCO23 https://t.co/q7FBOJSe33 (@OncLive)

Obecatagene autoleucel was associated with a 76% complete response (CR)/CR with incomplete count recovery rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. @drclaireroddie @uclcancer #ASCO2023 #ASCO23 #leusm https://t.co/1ZUt8ewXdp (@OncLive)

Brexu-cel elicited high rates of complete remission s/ MRD negativity in real-world patients w/ R/R B-cell acute lymphoblastic leukemia who received the CAR T-cell product as post-approval, standard-of-care treatment. @RoloffGreg @UChicagoMed @ASCO #ASCO23 https://t.co/DbYMoQThvh (@OncLive)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study https://t.co/jCCH7OfjhM #ALL #leusm (@smbenlazar)

Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4 rearrangement https://t.co/FeW8AfnyhC (@smbenlazar)

Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4 rearrangement https://t.co/FeW8AfnyhC (@smbenlazar)

Changes in the IKZF1 gene are linked to poor outcomes for children with B-cell acute lymphoblastic leukemia. Dr. Ruth Wang'ondu will explain why Dec. 10 at 10:15 am CT https://t.co/xjgc1o0IyP @wang_rwang #ASH22 (@StJudeResearch)

Dr. Ruth Wang'ondu will present “The Role of Ikaros (IKZF1) Alterations in B-Acute Lymphoblastic Leukemia” Dec. 10 at 6:30 pm CT during the Promoting Minorities in Hematology Session. https://t.co/ZFnvA9TtpR #ASH22 @wang_rwang (@StJudeResearch)

https://t.co/CgHY7tc2sw #ASH22 Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial (@TalhaBadarMD)

Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial https://t.co/W6kcXnS2cg #lesm (@smbenlazar)

NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia | Nature Immunology https://t.co/BwHvhTn7yH (@DrDanPersky)

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia https://t.co/OPIycIZLYz (@jamecancerdoc)

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations | Blood | American Society of Hematology https://t.co/tegs0oxd9P (@syed_abutalibmd)

Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia | Nature Medicine https://t.co/E4P8yfYWNp (@weldeiry)

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia #bmtsm #leusm #CARTcell @ASTCT_Journal https://t.co/BrCfnYyIQH (@BldCancerDoc)

At #ASH21, he’s presenting preliminary data of a study of allogeneic, CD-19 directed CAR T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia. View the data: https://t.co/8u1fbQWLsV @NitinJainMD #EndCancer (@MDAndersonNews)

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia https://t.co/kXE9Cf0car (@PLMcCarthyMD)

Low toxicity & high durability of CD19 CAR-T cell therapy without allo-SCT offers new possibility for refractory adult B cell acute lymphoblastic leukemia https://t.co/JsFMh03sfg #ALL #JCO #leusm @drclaireroddie (@ASCO_pubs)

Durable responses + low toxicity after fast off-rate CD19 CAR-T therapy in adults with relapsed/refractory B-cell acute lymphoblastic #leukemia Our new paper in @ASCO Journal of Clinical Oncology by @drclaireroddie @uclcancer et al. on the ALLCAR19 trial https://t.co/vJj14FbB9X (@DrGWheeler)

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia https://t.co/yLbra4K9hx @drclaireroddie et al. (@pebarba)

At a median follow-up of 4.8 years, the median overall survival was 10.5 months with CD19.28ζ-directed CAR T cells in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. @NiraliShahMD #leusm https://t.co/kMLyM8UvPl (@OncLive)

A long-term @theNCI @NCI_CCR_PedOnc follow-up study of CD19-CAR T-cell therapy in children and young adults with B-cell acute lymphoblastic #leukemia found 62% of patients achieved a complete remission. https://t.co/WLiu6ILKgO #CART #immunotherapy (@NCIBillDahut)